AVEO Oncology (AVEO: Quote) announced Thursday that Nasdaq halted trading of its common stock this morning, May 2, 2013. The company also stated that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee or ODAC meets today to discuss the New Drug Application or NDA for tivozanib for the treatment of patients with advanced renal cell carcinoma or RCC.
According to the timelines established by the Prescription Drug User Fee Act or PDUFA, the review of the NDA is expected to be complete by July 28, 2013.
The company noted that it will host a conference call today at 4:30 p.m. (ET) to discuss the ODAC panel’s review of the tivozanib NDA.
Click here to receive FREE breaking news email alerts for AVEO Pharmaceuticals, Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News